Synergistic effects of low-dose chemotherapy and T cells in renal cell carcinoma

DAN-DAN XU1,2*, MEN DING2,3*, PAN TONG2,4, YAN-YUN CHONG2, WEI-YU GU2, YANG LI2, XIN-JIANG FANG1 and NING LI5

1Center of Clinical Oncology, Second People's Hospital, Lianyungang, Jiangsu 222000; 2Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002; 3Department of Urology, Dushu Lake Hospital, The Affiliated Hospital of Suzhou University, Suzhou, Jiangsu 215005; 4Department of ICU, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002; 5Department of Neurosurgery, Lianyungang Hospital, Affiliated to Xuzhou Medical University, Lianyungang, Jiangsu 222002, P.R. China

Received June 29, 2019; Accepted May 8, 2020

DOI: 10.3892/or.2020.7679

Abstract. Renal cell carcinoma (RCC) is not sensitive to conventional radiotherapy and chemotherapy, and the effectiveness rate of molecular targeted therapy is low. Therefore, it is urgent to identify new treatment methods. Recently, adoptive T-cell therapy has provided a new option for cancer treatment. Furthermore, low-dose chemotherapy not only has no evident side effects and inhibitory effects on the human immune system, but can also enhance the immune activity of some effector cells. Therefore, it is surmised that the combination of different mechanisms of chemotherapy and immunotherapy could be a new treatment concept. In the present study, the effects of low-dose chemotherapy combined with T cells in the treatment of renal cell carcinoma were explored using cytotoxicity assays, enzyme-linked immunosorbent assay (ELISA), western blot analysis and flow cytometric analysis. The results revealed that low-dose chemotherapy and T cells had synergistic effects on tumor cell elimination in vitro. The transforming growth factor (TGF)-β signaling pathway may be involved in the inhibition of T-cell functions. The targeted inhibition of TGF-β signals may be a promising therapeutic strategy for the treatment of renal cancer. The present results provided a novel strategy for the combination of low-dose chemotherapy and T cells to enhance the therapeutic efficacy of RCC treatment.

Introduction

Renal cell carcinoma (RCC) is a common malignant tumor of the urinary system in adults, accounting for 3% of all cancer cases (1). In recent years, the incidence of RCC has been increasing annually; its degree of malignancy is extremely high, and it is difficult to detect in the early stage (2). By the time it is first diagnosed, 30% of RCC patients present with tumor metastases (3), and the survival rate of patients with metastatic RCC can be as low as 9.5% (4). Renal cancer is not sensitive to conventional chemo-radiotherapy and the effectiveness of molecular targeted therapy is low. Therefore, exploring effective treatment methods for RCC is of great significance for improving the survival rate of patients with RCC.

Cytotoxic T lymphocytes (CTLs) are specific immune defense effector cells of the immune system. Several factors affect their killing effects on tumors, such as the secretion of interferon (IFN)-γ and tumor necrosis factor (TNF) and the distance between CTLs and tumors (5). Clinical results have revealed that T-cell persistence can improve therapeutic responses, and immune memory can enhance T-cell persistence (6,7). As a result, immune memory is essential for therapeutic responses. Preclinical animal models have also confirmed that memory T cells are key to antitumor effects, including central memory T (T(CM)) and effector memory T (T(EM)) cells (8). CD4+ T cells are indispensable for functional CD8+ T cell memory formation (9). In addition, CD4+ T cells play several roles in cancer treatment, including enhancing the activation, recruitment, proliferation and cytotoxic function of CD8+ T cells and directly inhibiting tumor growth (10,11). Given the functions of CD4+ T cells, these T cells were used in the present experiments. CTLL-2 cells isolated from C57/BL/6 inbred mice are mouse-derived cytotoxic T cells, and the signaling pathway in CTLL-2 cells can be used as a model in CTL cells (12).

Correspondence to: Professor Ning Li, Department of Neurosurgery, Lianyungang Hospital, Affiliated to Xuzhou Medical University, 182 Tongguan North Road, Haizhou, Lianyungang, Jiangsu 222000, P.R. China
E-mail: ln6534@163.com

Professor Xin-Jiang Fang, Center of Clinical Oncology, Second People's Hospital, 41 Hailian East Road, Haizhou, Lianyungang, Jiangsu 222000, P.R. China
E-mail: 13851209662@126.com

*Contributed equally

Key words: RCC, immunotherapy, T cells, low-dose chemotherapy, DDP, MMC
As an important tumor treatment method, chemotherapy can kill cancer cells in the rapid proliferation stage. However, the dose and duration of the effects of chemotherapeutic drugs are limited by acute and cumulative toxicity in normal tissues (13,14). Hence, it is urgent to identify anticancer treatments with natural properties, low toxicity, and high efficacy. Low-dose chemotherapy not only has no significant side effects or inhibitory effects on the immune system, but can also improve the immune activity of some effector cells (15). In the present study, diaminedichloroplatinum (DDP) and mitomycin C (MMC), two traditional broad-spectrum chemotherapeutic drugs used for various types of tumors (16), were selected to study the toxicity of low-dose drugs in tumor cells. DDP is a nonspecific chemotherapeutic drug that can inhibit proliferation and promote apoptosis in tumor cells (17), and it has been used for several years in clinical tumor treatment (18). MMC is also widely used for the treatment of various types of cancer, such as bladder, stomach and cervical cancer (19). These two drugs were selected with the purpose of extending this approach to more tumors than just renal cancer.

The rapid development of immunotherapy has generated a fourth therapy for cancers, which can be used in parallel with surgery, chemotherapy and radiotherapy (20). Cellular immunotherapy can recognize a small number of tumor cells and has powerful lethal and targeting effects (21). Therefore, low-dose chemotherapy combined with cellular immunotherapy is of great significance for clearing small lesions and reducing recurrence rate in patients. In the present study, the synergistic killing effect of low dose-chemotherapy combined with T cells on RCC cells in vitro was observed and the possible underlying synergistic mechanisms were explored. The present results provided a new concept and an experimental basis for the comprehensive treatment of RCC.

Materials and methods

Cell culture and chemotherapy treatment. The RCC cell lines RENCA and ACHN and the mouse-derived cytotoxic T cells CTLL-2 were obtained from the Jiangsu Cancer Biotherapy Institute, Xuzhou Medical University (Xuzhou, China). RENCA and CTLL-2 cells were cultured in RPMI-1640 medium and ACHN cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco; Life Technologies; Thermo Fisher Scientific, Inc.). All media were supplemented with 10% fetal bovine serum (FBS; Gibco; Life Technologies; Thermo Fisher Scientific, Inc.) and 1% penicillin-streptomycin (Sangon Biotech Co., Ltd.). RCC cells were detached using 0.25% trypsin (Beyotime Institute of Biotechnology). All cells were maintained in incubators (Thermo, Fisher Scientific, Inc.) with 95% air and 5% CO2 at 37°C.

DDP and MMC were purchased from Jiangsu Hansoh Pharmaceutical Group Co., Ltd. and Vicmed, respectively. The concentration of the DDP storage solution was 5 mg/ml. Two milligrams of MMC powder was dissolved in phosphate-buffered saline (PBS) to prepare a 2 mg/ml stock solution. For chemotherapy treatment and antitumor analysis, renal cancer cells were treated with serially diluted doses of DDP or MMC for 24 h. In order to avoid the cumulative toxicity of drugs, tumor cells treated with drugs for 24 h were used to co-incubate with T cells (Fig. 1A).

Preparation of T cells. Ten 4-week-old female BALB/c mice weighing 16 g (Huafukang Bioscience) were raised with the feed and sterile water for 1 week at our well-ventilated animal facility with 25°C, humidity of 60% and a 12-h light/dark cycle before testing was initiated. The Animal Experimental Ethics Committee of Xuzhou Medical University approved all the animal studies. The mice were sacrificed by cervical dislocation and the disappearance of a blink reflex indicated the death of the mice. T cells were isolated from the lymph nodes and spleen of mice with an EasySep™ Mouse T Cell Isolation Kit (STEMCELL Technologies, Inc.). T cells were cultured in RPMI-1640 complete medium at a cell density of 1x10⁶/ml and activated by CD3 antibody (5 µg/ml) and CD28 antibody (2 µg/ml; both from Sigma-Aldrich; Merck KGaA). Peripheral blood mononuclear cells (PBMCs) from a 25-year-old female healthy blood donor who agreed to use her samples in scientific research were collected and isolated by density gradient centrifugation at our institute. The inclusion of human subjects in our study was approved by the Ethics Committee of the First People’s Hospital of Lianyungang and the informed consent was obtained from the blood donor. T cells were isolated with an EasySep™ Human T Cell Isolation Kit (STEMCELL Technologies, Inc.) and amplified using a Dynabeads® Human T-Expander CD3/CD28 Kit (Thermo, Fisher Scientific, Inc.). T cells were activated in RPMI-1640 complete medium with 300 IU/ml interleukin (IL)-2 (SL PHARM) at a cell density of 1x10⁶/ml. After 48 h of activation, the T cells were used for subsequent experiments.

Flow cytometric analysis. Flow cytometry was used to detect the surface expression of CD4 and CD8 in T cells. The antibodies used for staining were purchased from BD Biosciences and included anti‑mouse CD4-FITC antibody (Cat. no. 557667), anti‑mouse CD8-PE antibody (Cat. no. 557086) and anti‑human CD8-phycoerythrin antibody (Cat. no. 557086). A total of 1x10⁶ T cells were incubated in 100 µl PBS with 0.5 µl fluorescence-labeled antibody for 30 min at room temperature in the
Figure 1. Killing effect of T cells combined with low-dose chemotherapy on renal cancer cells. (A) Time axis of low-dose chemotherapy combined with T cells. (B) Determination of low-dose drug concentrations. A CCK-8 assay was performed to determine the concentrations of DDP and MMC that resulted in an inhibition rate of <30% after 24-h treatment in RCC cells. (C) Expression of CD4 and CD8 in purified T cells. CD4 and CD8 expression levels in T cells isolated and purified from (a) mice and (b) humans were verified by FACS analysis. (D) Specific cytotoxicity exhibited by T cells toward RCC. The cytotoxic activity of T cells toward RCC cells was determined by (a) LDH and (b) CCK-8 assays. (E) Synergistic effects of low-dose chemotherapy and T cells on RCC cells. RCC cells treated with 1 µg/ml DDP or 0.1 µg/ml MMC for 24 h were coincubated with T cells for 6 h. The cytotoxic activity of T cells was determined by (a and d) CCK-8 assay, (b and e) luciferase assay and (c) LDH release assay. *P<0.05; **P<0.01; ***P<0.001; ns, not significant. RCC, renal cell carcinoma; DDP, diaminodichloroplatinum; MMC, mitomycin C; LDH, released lactate dehydrogenase; CCK-8, Cell Counting Kit-8.
An FITC-Annexin V Apoptosis Detection Kit (Nanjing KeyGen Biotech Co., Ltd.) was used to detect the effects of chemotherapeutic drugs on apoptosis in RCC cells. The antibodies used for staining were purchased from BD Biosciences and included anti-CD8-PerCP-Cy5.5 (cat. no. 551162), anti-CD62L-allophycocyanin (APC; cat. no. 561919), anti-CD44-PE (cat. no. 561860), and anti-programmed death factor 1 receptor/ligand (PD-L1)-APC (cat. no. 564715). A total of 1x10⁶ T cells were stained with 0.5 µl fluorescence-labeled antibody in 100 µl PBS for 30 min at room temperature in the dark, and then the stained T cells were detected using a flow cytometer.

Cytotoxicity assay. T cells were cultured with target cells (RENCA/ACHN) in 96-well plates at effector-to-target (E/T) ratios of 40:1, 20:1, 10:1 and 5:1 for 6 h (6,23). The released lactate dehydrogenase (LDH) in the supernatants was assessed using the CytoTox 96® Non-Radioactive Cytotoxicity Test Kit (Promega Corporation) according to the manufacturer's recommendations. The specific cytotoxicity was calculated according to the formula: % Cytotoxicity=100x[(experimental release)/(target spontaneous release -target minimal release)/(target maximal release -target spontaneous release)].

Statistical analysis. The data were presented as the mean ± standard deviation (SD) of three independent experiments. The data were analyzed using SPSS statistical software version 18.0 (SPSS, Inc.). Comparisons between two groups were performed using a two-tailed Student's t-test. One-way ANOVA and Tukey's post hoc test were used when more than two groups were compared. Differences with P<0.05 were considered statistically significant.

Results

Killing effects of T cells combined with low dose chemotherapy on renal cancer cells in vitro. CCK-8 assays were performed to determine the concentrations of DDP and MMC with an inhibitory rate of <30% in the early stage (24 h). The inhibitory effects of DDP or MMC on RCC cells were revealed to be dose-dependent. As drug concentrations increased, the survival rate was obviously decreased in RCC cells (RENCA/ACHN) were exposed to 1 µg/ml DDP or 0.1 µg/ml MMC for 24 h, and then the TGF-β in the supernatant was analyzed. RCC cells that had been exposed to 1 µg/ml DDP or 0.1 µg/ml MMC for 24 h were cultured in medium for another 24 h. The TGF-β level in the supernatant was assayed by an ELISA kit [MultiSciences (Lianke) Biotech, Co., Ltd.] according to the manufacturer's recommendations.
cells when compared with untreated cells (Fig. 1B). After 24 h
that of treatment with drugs, the viabilities of RENCA and
ACHN cells were 73.85±0.35 and 82.89±2.07%, respectively,
in the DDP (1 µg/ml) group and 88.58±2.68 and 75.35±3.75%,
respectively, in the MMC (0.1 µg/ml) group (Table I).

FACS was used to assess the surface expression of CD4
and CD8 in purified mouse or human T cells. The percent-
ages of CD4 and CD8 cells were 38.1±0.14 and 31.7±0.42%,
respectively, in mouse T cells and 52.1±1.27 and 32.65±0.49%,
respectively, in human T cells (Fig. 1C). To evaluate the
cytotoxic effects of T cells against renal cancer cells, lactate
dehydrogenase (LDH) release assays and CCK-8 assays were
performed. As revealed in Fig. 1D, with the increase in the E/T
ratio, the killing activity of T cells against RENCA and ACHN
cells was enhanced compared to that in the 5:1 E/T ratio group.
Therefore, an E/T ratio of 10:1 was used for all subsequent
in vitro studies.

To explore whether DDP or MMC treatment could
increase the sensitivity of RCC cells to T cell-mediated lysis,
RENCA and ACHN cells were treated with drugs for 24 h
and then used as target cells in LDH release assays, CCK-8
assays, and Luc assays. The results revealed that DDP and
MMC significantly increased the sensitivity of RENCA and
ACHN cells to the effects of T cells (Fig. 1E). Collectively,
the results revealed that DDP and MMC was capable of
altering renal cancer cells to render them more amenable to
T cell-mediated attack, and low-dose chemotherapy and the
T cells exhibited a synergistic killing effect on renal cancer
cells in vitro.

Effect of low-dose chemotherapy on renal cancer cells in vitro.
First, the CCK-8 method was utilized to assay the effect of
DDP and MMC on the proliferation of RENCA and ACHN
cells. RENCA and ACHN cells were exposed to 1 µg/ml DDP
or 0.1 µg/ml MMC for 0, 24, 48, or 72 h, and the viability of
RENSA and ACHN cells was significantly decreased as the
reaction time increased (Fig. 2A; Table II). Then, FACS was
used to assess the apoptosis rates of RENCA and ACHN cells
treated with chemotherapy drugs (24 h) or chemotherapy
combined with T cells (48 h). Compared with those of untreated
cells, the apoptosis rates of RCC cells treated with DDP or
MMC were significantly increased (Fig. 2B; Table III). These
data also revealed that low-dose chemotherapy and T cells had a
synergistic apoptotic effect on renal cancer cells in vitro. Finally,
western blot analysis was performed to detect the expression of
transforming growth factor-β receptor 1 (TGF-βR1) in renal
cancer cells treated with DDP or MMC for 4 h and 12 h. The
results revealed that DDP and MMC significantly decreased
the expression of TGF-βR1 compared with untreated cells,
indicating that chemotherapy drugs could inhibit the expression
of immune-related proteins in the early stage of treatment to
enhance the anti-tumor effect of T cells (Fig. 2C).

Effect of low-dose chemotherapy on T cells in vitro. To
investigate whether chemotherapy drugs could enhance the
specificity and activation of T cells, cytokine release assays
were performed. T cells were co-cultured with RCC cells that
had been treated with DDP or MMC for 24 h at an E/T ratio of
10:1. After 6 h of incubation, the IFN-γ cytokine expression
of CTL-2 cells in the drug groups was significantly higher than
that in the CTL-2 untreated group (Fig. 3A). These results

| Drug concentration (µg/ml) | Viability at 24 h (%) | Drug concentration (µg/ml) | Viability at 24 h (%) |
|---------------------------|----------------------|---------------------------|----------------------|
| RENCA cells               |                      | ACHN cells                |                      |
| 0                         | 100.00±2.95          | 0                         | 100.00±3.35          |
| 0.25                      | 92.52±1.07          | 0.5                       | 92.49±3.94          |
| 0.5                       | 84.28±0.01         | 1                         | 82.89±2.07          |
| 1                         | 73.85±0.35         | 2.5                       | 77.07±4.72          |
| 2.5                       | 55.42±1.58         | 5                         | 39.38±3.44          |
| 5                         | 44.85±7.32         | 10                        | 27.25±2.29          |
| 10                        | 38.86±6.87         | 20                        | 15.57±2.07          |
| MMC                       |                      |                            |                      |
| 0                         | 100.00±2.69          | 0                         | 100.00±1.49          |
| 0.05                      | 97.99±0.41         | 0.005                     | 99.84±13.33         |
| 0.1                       | 88.58±2.68         | 0.01                      | 93.84±4.25          |
| 0.5                       | 76.82±2.00         | 0.05                      | 90.56±1.32          |
| 1                         | 56.28±4.47         | 0.1                       | 75.35±3.75          |
| 5                         | 28.78±2.05         | 0.5                       | 55.46±3.86          |
| 10                        | 20.97±1.06         | 1                         | 37.55±1.69          |

*P>0.05 (ns) or *P<0.05, compared with the untreated DDP (0 µg/ml) group; *P>0.05 (ns) or *P<0.05, compared with the untreated MMC
(0 µg/ml) group. RCC, renal cell carcinoma; DDP, diamminedichloroplatinum; MMC, mitomycin C; ns, not significant.
Figure 2. Effects of low-dose chemotherapy on renal cancer cells. (A) Effects of DDP and MMC on the viability of RCC cells. RENCA and ACHN cells treated with 1 µg/ml DDP or 0.1 µg/ml MMC for 0, 24, or 72 h were assayed for viability by a CCK-8 assay. (B) Effects of the drugs (DDP or MMC) or drugs combined with T cells on the apoptosis of RCC cells. FACS was used to assess the apoptotic rates of (a) RENCA and (b) ACHN cells treated with 1 µg/ml DDP, 0.1 µg/ml MMC for 24 h or drugs combined with T cells sequentially for another 24 h. (C) Effects of DDP and MMC on TGF-βR1 expression in RCC cells. The TGF-βR1 expression in RENCA and ACHN cells treated with DDP or MMC for 4 and 12 h was assessed by western blot analysis. Actin was used to normalize the protein content. "P<0.01; ""P<0.001; """"P<0.01 vs. the CTRL; **""""P<0.001 vs. the CTRL; ns: not significant. RCC, renal cell carcinoma; DDP, diaminedichloroplatinum; MMC, mitomycin C; CCK-8, Cell Counting Kit-8; TGF-βR1, transforming growth factor-β receptor 1; CTRL, control.
indicated that the DDP and MMC could specifically promote IFN-γ cytokine expression to enhance the killing effect of T cells in early stages. However, the level of the cytokine IFN-γ in the drug-treated group was significantly reduced after 24 h of incubation (Fig. 3A).

Cell migration assays were performed using a Transwell system. As revealed in Fig. 3B, a significantly higher number of CTLL-2 or T cells passed through the membrane into the lower chamber in the drug group than in the untreated group after 6 h of incubation with RCC cells. These results indicated that DDP and MMC could promote the migration of T cells to tumor sites to enhance the killing effect of T cells in the early stages. However, the migration of T cells in the drug group was significantly inhibited, and even the number of T cells was decreased compared to that in the untreated CTLL-2 or T cell group after 24 h of incubation (Fig. 3B).

It has been previously reported that chemotherapy can alter the phenotype of T cells to render them more sensitive to tumor cells (25). To determine whether DDP or MMC could regulate the cell surface marker expression, T cells were co-cultured with RENCA cells that had been treated with DDP or MMC for 24 h, and then the T cells were stained and analyzed by flow cytometry. DDP increased the percentage of CD8+CD44+CD62L+T cells and decreased the percentage of CD8+CD44+CD62L-T cells compared with the untreated cell group (Fig. 3C; Table IV). These data indicated that low-dose DDP could promote the transformation of effector memory T cells into central memory T cells to enhance the cytotoxicity of T cells toward tumor cells. Compared with the untreated cell group, DDP and MMC also significantly decreased PD1 expression in T cells (Fig. 3C; Table IV). The altered expression of these markers may aid in T cell cancer-killing effects.

Possible causes of the functional inhibition of T cells in vitro.

To explore the causes of the decreased secretion of T-cell immune factors and the inhibition of T-cell migration toward tumor sites at 24 h, cytokine release assays and western blot analyses were performed to detect the expression of the cytokine TGF-β and the TGF-βR1 and Smad2 proteins in renal cancer cells. Compared with those in the control (CTRL) group, RCC cells in the DDP and MMC groups had stronger expression of TGF-β cytokine and TGF-βR1 and Smad2 proteins, although the increase in TGF-βR1 expression in RENCA cells in the DDP group was not statistically significant (Fig. 4A and B; Table V). TGF-βR1 and Smad2 protein expression in CTLL-2 and T cells was also detected. In the DDP and MMC groups, TGF-βR1 and Smad2 protein expression was significantly higher than that in the control group (Fig. 4C). These results indicated that the TGF-β signaling pathway may be involved in inhibiting T-cell function.

Discussion

RCC is a malignant tumor that seriously affects human health. Thirty percent of RCC patients have metastatic lesions at the time of diagnosis. At present, there are no effective drugs for patients with metastasis (4,26). Thus, the treatment of RCC represents an unmet clinical need and the discovery of innovative approaches for this purpose is urgently required. In the present study, low-dose chemotherapy combined with T cell immunotherapy, and the combination of the two methods had synergistic effects on renal cancer cell treatment in vitro. However, the tumor microenvironment (TME) in the body is a complex system composed of numerous cells that regulate different immune responses (27). The development of standardized, individualized chemotherapy combined with

Table II. Effects of DDP and MMC on the proliferation of RCC cells.

| Group | Drug concentration (µg/ml) | 0 h     | 24 h     | 48 h     | 72 h     |
|-------|---------------------------|---------|---------|---------|---------|
| RENCA | DDP (1)                   | 105.70±1.16 | 73.85±0.35 a | 54.71±5.63 b | 43.51±1.11 b |
|       | MMC (0.1)                 | 105.65±4.03 | 88.58±2.68 a | 84.44±6.39 c | 78.58±4.64 c |
| ACHN  | DDP (1)                   | 100.20±1.71 | 82.89±2.07 a | 72.69±6.39 c | 56.31±4.63 c |
|       | MMC (0.1)                 | 105.60±1.85 | 75.35±3.75 a | 51.10±8.21 b | 31.65±1.95 b |

aP<0.05, compared with the drug-treated 0-h group; bP<0.05 or P>0.05 (ns), compared with the drug-treated 24-h group; cP<0.05 or P>0.05 (ns), compared with the drug-treated 48-h group. RCC, renal cell carcinoma; DDP, diamminedichloroplatinum; MMC, mitomycin C; ns, not significant.

Table III. Apoptosis of RCC cells treated with drugs or combined with T cells (%).}

| Group | Viability (%, mean ± SD) |
|-------|--------------------------|
| CTRL  | 10.90±0.14              |
| DDP + T | 23.90±1.13           |
| MMC + T | 22.80±0.85          |
| DDP   | 18.50±0.57 a           |
| MMC   | 13.90±0.17 a           |
| T     | 17.25±0.78 a           |
|       | 6.15±0.21              |
|       | 15.65±0.49             |
|       | 20.55±0.78             |
|       | 11.20±1.27 b           |
|       | 10.50±0.28 a           |
|       | 11.70±0.14 b           |

aP<0.05, compared with the CTRL group; bP<0.05, compared with the combined group (DDP + T); cP<0.05, compared with the combined group (MMC + T). RCC, renal cell carcinoma; CTRL, control, DDP, diamminedichloroplatinum; MMC, mitomycin C.
immunotherapy with few side effects is the main direction of future research.

DDP and MMC are two of the earliest discovered chemotherapeutic agents and are the most widely used drugs (28). To avoid long-term and delayed side effects, low-dose chemotherapy drugs combined with T cell therapy was used to treat RCC. One of the main methods of cancer treatment is to induce apoptosis in cancer cells (29). Most chemotherapy drugs rely on the induction of apoptosis for efficacy (28). It has been reported that MMC and DDP can effectively inhibit tumor growth or significantly increase tumor apoptosis in rapidly proliferating cell populations (15,28,30). The present study revealed that low-dose chemotherapy could also inhibit proliferation and induce apoptosis in renal cancer cells. When combined with T cells, low-dose chemotherapy had a synergistic effect in inducing the apoptosis of renal cancer cells. Several studies have revealed that some chemotherapeutic drugs, such as DDP or MMC, in addition to their direct cytotoxic effects on tumor cells, can also regulate the antitumor immune response (25,31,32). In the present study it was revealed that DDP and MMC inhibited the expression of the immune-related protein TGF-βR1 in renal cancer cells in the early stage (4 or 12 h). TGF-βR1 is an important element of the TGF-β/SMAD signaling pathway, which has emerged as a central mediator of cancer progression due to its capacity to regulate cell growth, differentiation, and migration (33,34).

Adoptive T cell therapy provides a new treatment option for advanced cancer patients. Chemotherapeutic drugs can effectively induce immune responses by increasing the cross-presentation of tumor antigens, influencing the expression of cytokines and the migration of effector T cells, affecting production of immune memory, and reducing the number of immunosuppressive cells (35,36). The present study revealed that the combination of T cells with DDP or MMC increased the killing effect on renal cancer cells. Cytokines are important in maintaining or enhancing the function of T cells, and IFN-γ secretion was detected in T cells. The results revealed that low doses of the chemotherapeutic drugs DDP and MMC promoted IFN-γ secretion in the early stage (6 h) to enhance the antitumor effect. T cells must penetrate tumor sites to play their antitumor role effectively. Therefore, the effect of chemotherapeutic drugs on T-cell chemotaxis was examined. The results revealed that DDP and MMC could promote T cell infiltration into tumor cell sites at the early stage (6 h) to enhance the antitumor effect of T cells. CD8+ (CD44+ CD62L+) TCMs, with greater proliferation and survival potential than with CD8+ (CD44+ CD62L-) TEM, are pivotal for antitumor efficacy (6,8). The present results revealed that DDP could induce the transformation of T cells from effector memory T cells into central memory T cells, which is of great significance for T cells in exerting sustainable killing effects on tumor cells. Programmed death factor 1 receptor/ligand (PD1/PD-L1) plays an important role in regulating T cell immunity and has become a research hotspot in immunotherapy in recent years. PD1/PD-L1 can inhibit T-cell activation and proliferation, weaken the antitumor immune response, and negatively regulate immune responses (37). PD1 is expressed at various levels mainly on the surface of activated T cells (38). The present results revealed that chemotherapeutic drugs (DDP/MMC) could reduce PD1 expression in T cells to improve the persistence of T cells. A limitation of the present study was that FACS did not contain an isotype control. However, the antitumor

### Table IV. Effects of DDP and MMC on T cell subtypes (% mean ± SD).

| Groups   | CD8+ (CD44+CD62L+) | CD8+ (CD44+CD62L+) | PD1 |
|----------|--------------------|--------------------|-----|
| T        | 81.55±0.21         | 15.23±0.59         | 19.93±0.01 |
| T+DDP    | 83.25±0.07a        | 13.17±0.61a        | 13.07±0.88a |
| T+MMC    | 82.05±1.20b        | 15.17±1.05b        | 14.93±3.32 |

aP<0.05 or bP>0.05 (ns), compared with each T-cell group. DDP, diamminedichloroplatinum; MMC, mitomycin C; PD1, programmed death factor 1; ns, not significant.

### Table V. Effects of DDP and MMC on TGF-β secretion of RCC cells (% mean ± SD).

| Drug concentration (µg/ml) | RENCA | AHN | 24 h  | 48 h  |
|---------------------------|-------|-----|-------|-------|
| CTRL (0)                  | 734.29±7.56 | 922.14±9.20 | 242.31±18.20 | 1,566.4±20.50 |
| DDP (1)                   | 851.97±26.22a | 1,172.8±6.70a | 530.13±16.16a | 657.25±36.20a |
| MM (0.1)                  | 880.53±36.8a | 1,363.9±16.0a | 459.38±0.0a | 606.27±21.87a |

The 48-h groups were another 24-h culture without drugs after 24-h treatment with drugs. aP<0.05, compared with each CTRL group. RCC, renal cell carcinoma; DDP, diamminedichloroplatinum; MMC, mitomycin C; TGF-β, transforming growth factor-β; CTRL, control.
Figure 3. Effects of low-dose chemotherapy on T cells. (A) Effects of DDP and MMC on the cytokine IFN-γ release of T cells. RENCA cells treated with 1 µg/ml DDP or 0.1 µg/ml MMC for 24 h were coincubated with T cells for 6 and 24 h. The levels of the cytokine IFN-γ released by T cells were measured by ELISA after incubation with RENCA cells at an E/T ratio of 10:1. (B) Effects of DDP or MMC on the migration of T cells. RENCA and ACHN cells treated with 1 µg/ml DDP or 0.1 µg/ml MMC for 24 h were coincubated with T cells for 6 and 24 h. The migration of T cells was measured by a Trypan blue counting assay after incubation with RENCA and ACHN cells at an E/T ratio of 10:1. (C) Effects of DDP or MMC on T cell phenotypes. RENCA cells treated with 1 µg/ml DDP or 0.1 µg/ml MMC for 24 h were coincubated with T cells for another 24 h. Phenotypes of T cells and CTLL-2 cells were analyzed by flow cytometry for CD8+CD44+CD62L+ and PD1 surface expression. (a) T-cell group; (b) T cells combined with the DDP group; (c) T cells combined with the MMC group; (d) CTLL-2 cell group; (e) CTLL-2 cells combined with the DDP group; (f) CTLL-2 cells combined with the MMC group. *P<0.05; **P<0.01; ***P<0.001; ns, not significant. DDP, diaminedichloroplatinum; MMC, mitomycin C; ELISA, enzyme-linked immunosorbent assay; IFN-γ, interferon γ; E/F, effector-to-target; PD1, programmed death factor 1 receptor.
effects of T cells depend on their activation, which is limited by a dual-signal system (39). Recently, chimeric antigen receptor-modified T (CAR-T) cells, which can transcend the dual signaling pathway and are not restricted by the major histocompatibility complex (MHC), have attracted wide attention (40,41). The present study provided a theoretical basis for the use of CAR-T cells combined with low-dose chemotherapy in the future.

In the later stage (24 h), it was revealed that chemotherapeutic drugs (DDP/MMC) inhibited IFN-γ secretion...
and T-cell chemotaxis, which may be related to the TGF-β signaling pathway. TGF-β/Smad2 signaling is a strong immunosuppressive factor. TGF-β can effectively inhibit the proliferation, activation, and infiltration of T cells and induce T-cell apoptosis to attenuate the killing activity of T cells in tumors (42-44). To study the possible causes, the expression of TGF-β, TGF-βR1, and Smad2 was examined in renal cancer cells and the expression of TGF-βR1 and Smad2 in T cells. It was determined that the expression of TGF-β, TGF-βR1, and Smad2 in renal cancer cells was significantly increased following DDP and MMC exposure in the later stage (48 h), and the expression of TGF-βR1 and Smad2 in T cells was also significantly increased. Therefore, it was theorized that the decreased secretion of immune factors and the inhibitory infiltration of T cells may be related to the TGF-β signaling pathway. It has been reported that the inhibitory effects of TGF-β on T-cell function could be reversed by using a small molecule inhibitor of TGF-βR1 signaling, and this molecule may function as an antitumor drug in the future (44). However, whether TGF-βR1 silencing could reverse the effects of DDP and MMC on renal cells was not explored, which is a limitation of the present study.

In conclusion, the present results revealed that low-dose chemotherapy drugs (DDP and MMC) have the potential to kill RCC cells, and treatment with DDP or MMC can inhibit proliferation and promote apoptosis in RCC. Low-dose chemotherapy drugs (DDP and MMC) can synergistically enhance the immunotherapeutic effects of T cells on RCC in vitro by inhibiting TGF-βR1 expression in tumor cells, promoting IFN-γ secretion, chemotaxis and phenotype changes of T cells and inhibiting PDI expression. It was also revealed that the TGF-β signaling pathway may be involved in inhibiting the function of T cells by decreasing immune factor secretion, preventing chemotaxis toward tumor cells and even promoting the apoptosis of T cells. The targeted inhibition of TGF-β signals may be a promising therapeutic strategy for the treatment of renal cancer. The present study was conducted in RCC cell lines in vitro. Future studies of this therapeutic strategy need to be performed in vivo. The present study provided a novel therapeutic option for sequential immune chemotherapy to enhance the therapeutic efficacy of T cells.

Acknowledgements
Not applicable.

Funding
The present study was supported by Jiangsu Planned Projects for Postdoctoral Research Funds (grant no. 1501060A) and Jiangsu Overseas Research and Training Program for University Prominent Young and Middle-aged Teachers and Presidents.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
NL and XJF conceived and designed the project. DDX, PT, YYC, WYG and YL performed the experiments. DDX and MD drafted and revised the manuscript. DDX, PT, YYC and MD analyzed and interpreted the data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
All applicable international, national, and institutional guidelines for the care and use of animals were followed. The inclusions of mouse and human subjects in the present study were approved by the Animal Experimental Ethics Committee of Xuzhou Medical University and the Ethics Committee of the First People's Hospital of Lianyungangand, respectively. Written informed consent was obtained from the blood donor.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Gansler T, Ganz PA, Grant M, Greene FL, Johnstone P, Mahoney M, Newman LA, Oh WK, Thomas CR Jr, Thun MJ, et al: Sixty years of CA: A cancer journal for clinicians. CA Cancer J Clin 60: 345-350, 2010.
2. Escudier B, Porta C, Schmieder M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillesen S and Horwich A; ESMO Guidelines Committee. Electronic address: Clinicalguidelines@esmo.org: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30: 706-720, 2019.
3. Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin 67: 7-30, 2017.
4. Russo P: Delayed systemic treatment in metastatic renal-cell carcinoma. Lancet Oncol 17: 1187-1189, 2016.
5. Farhood B, Najafi M and Mortazaei K: CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol 234: 8509-8521, 2019.
6. Kaartinen T, Luostarinen A, Maliniemi P, Keto J, Arvas M, et al: Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion. Cytotherapy 19: 689-702, 2017.
7. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, et al: Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118: 6050-6056, 2011.
8. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA and Restifo NP: Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115: 1616-1626, 2005.
9. Janssen EM, Lemmens EE, Wolf T, Christen U, von Herrath MG, Rioux-Leclercq N, Bex A, et al: Paradoxical increase in CD8+ T lymphocytes. Nature 421: 852-856, 2003.
10. Ho PC, Meeth KM, Tsai YC, Srivastava B, Bosenberg MW and Kaech SM: Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. Cancer Res 74: 3205-3217, 2014.
11. Bos R and Sherman LA: CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 70: 8368-8377, 2010.
12. Fukushima K and Yamashita K: Interleukin-2 carbohydrate recognition modulates CTLL-2 cell proliferation. J Biol Chem 276: 7351-7356, 2001.
13. Zhou XL, Wang WW, Zhu WG, Song YQ, Pan P and Tong YS: High expression of long non-coding RNA AFAP1-AS1 predicts chemoresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Mol Carcinog 55: 2095-2105, 2016.
14. So B, Maruo L, Olver I, Gowda R and Bezak E: Oesophageal cancer: Which treatment is the easiest to swallow? A review of combined modality treatments for resectable carcinomas. Crit Rev Oncol Hematol 113: 135-150, 2017.
15. Han SZ, Liu HX, Yang LQ, Cui LD and Xu Y: Piperine (PP) enhanced mitomycin-C (MMC) therapy of human cervical cancer through suppressing Bcl-2 signaling pathway via inactivating STAT3/NIκB. Biomed Pharmacother 96: 1403-1410, 2017.
16. Pan XY: Comparison of the cytotoxic effect of fresh garlic, diallyl trisulfide, 5-fluorouracil (5-FU), mitomycin C (MMC) and Cis-DDP on two lines of gastric cancer cells. Zhonghua Zhong Liu Za Zhi 7: 103-105, 1985 (In Chinese).
17. Hu X, Ma J, Vikash V, Li J, Wu D, Liu Y, Zhang J and Dong W: Thymoquinone augments cisplatin-induced apoptosis on esophageal carcinoma through mitigating the activation of JAK2/STAT3 Pathway. Dig Dis Sci 63: 126-134, 2018.
18. Gomoy Y, Sasaki J, Branch C, Roth JA and Mukhopadhyay T: 5-aza-2-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells. Oncogene 23: 6779-6787, 2004.
19. Inman BA, Stauffer PR, Craciunescu OA, Maccarini PF, Dewhirst MW and Vujaskovic Z: A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. Int J Hyperthermia 30: 171-175, 2014.
20. Rosenberg SA and Restifo NP: Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348: 62-68, 2015.
21. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhalo Y and June CH: Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 32: 189-225, 2014.
22. Inamura SO, Ito H, Taga M, Kusuhara Y, Kobayashi M and Yokoyama O: Low-dose docetaxel enhanced the anticancer effect of temsirolimus by overcoming autophagy in prostate cancer cells. Anticancer Res 39: 5417-5425, 2019.
23. Zhang Q, Tian K, Xu J, Zhang H, Li L, Fu Q, Chai D, Li H and Zheng J: Synergistic effects of cabozantinib and EGFR-Specific CAR-NK-92 cells in renal cell carcinoma. J Immunol Res 2017: 6915912, 2017.
24. Tang Y, Tang Y and Cheng YS: MiR-34a inhibits pancreatic cancer progression through Snail-mediated epithelial–mesenchymal transition and the Notch signaling pathway. Sci Rep 7: 38323, 2017.
25. Zitvogel L, Apetoh L, Ghiringhelli F and Kroemer G: Immunochemical aspects of cancer chemotherapy. Nat Rev Immunol 8: 59-73, 2008.
26. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, et al: EAU guideline on renal cell carcinoma: 2014 update. Eur Urol 67: 913-924, 2015.
27. Mbeunkui F and Johann DJ Jr: Cancer and the tumor micro-environment: A review of an essential relationship. Cancer Chemother Pharmacol 63: 571-582, 2009.
28. Gao XH, Ni J, Xue JL and Wang X: Phyllanthus emblica Linn. fruit extract potentiates the anticancer efficacy of mitomycin C and cisplatin and reduces their genotoxicity to normal cells in vitro. J Zhejiang Univ Sci B 18: 1031-1045, 2017.
29. Czabator PÆ, Lessege G, Strasser A and Adams JM: Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat Rev Mol Cell Biol 15: 49-63, 2014.
30. Ye LY, Hu S, Xu HE, Xu RR, Kong H, Zeng XN, Xie WP and Wang H: The effect of tetranderine combined with cisplatin on proliferation and apoptosis of A549/DDP cells and A549 cells. Xinxi Yiya Liuhe Za Zhi 17: 40, 2017.
31. Huang X, Chen YT, Song HZ, Huang GC and Chen LB: Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells. World J Gastroenterol 17: 3002-3011, 2011.
32. Bergmann-Leitner ES and Abrams SI: Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother 50: 445-455, 2001.
33. Vollheger MA, Kappers I, Klomp HM, Buning-Kager JC, Korse CM, Hauptmann M, de Visser KE, van den Heuvel MM and Linn SC: Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 5: 1939-1948, 2010.
34. Heuer JG, Harlan SM, Yang DD, Jaqua DL, Boyles J, Wilson JM, Heinz-Tanhy KM, Sullivan JM, Wei T, Qian HR, et al: Role of TGF-alpha in the progression of diabetic kidney disease. Am J Physiol Renal Physiol 312: F951-F962, 2017.
35. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Freilinger JA and Robinson BW: Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-presentation rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170: 4905-4913, 2003.
36. Huang X, Guan D, Shu YQ, Liu JK and Ni F: Effect of cisplatin on the frequency and immuno-inhibitory function of myeloid-derived suppressor cells in a375 melanoma model. Asian Pac J Cancer Prev 16: 4329-4333, 2015.
37. Liu J, Zhong Y, Peng S, Zhou X and Gan X: Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: A meta-analysis. Onco Targets Ther 11: 8623-8632, 2018.
38. Chan TSY, Li J, Loong F, Khong PL, Tse E and Kwong YL: PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: Efficacy and safety. Ann Hematol 97: 193-196, 2018.
39. Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS and Lim WA: Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164: 770-779, 2016.
40. Chen DS and Mellman I: Oncology meets immunology: The cancer-immunity cycle. Immunity 39: 1-10, 2013.
41. Jackson HJ, Rafiq S and Brentjens RJ: Driving CAR T-cells forward. Nat Rev Clin Oncol 13: 370-383, 2016.
42. Yang J, Wahdan-Alaswad R and Danielpour D: Critical role of Smad2 in tumor suppression and transforming growth factor-beta-induced apoptosis of prostate epithelial cells. Cancer Res 69: 2185-2190, 2009.
43. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, et al: TGFβ1 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554: 544-548, 2018.
44. di Bari MG, Castiglioni A, Roybal KT, Koeppen H, Astarita JL, Cubas R, et al: TGFβ1 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554: 544-548, 2018.